Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q FilingBusiness Wire · Oct 19, 2026
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical ComparisonDefense World · Oct 17, 2026
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual MeetingBusiness Wire · Oct 16, 2026
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowZacks Investment Research · Oct 14, 2026
Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge GoldAccesswire · Oct 13, 2026
Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British ColumbiaAccesswire · Oct 8, 2026Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio).
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 31, 2026 | $0.85 | $0.85 | Beat |
| Apr 30, 2026 | $0.83 | $0.71 | Miss |
| Feb 12, 2026 | $0.73 | $0.63 | Miss |
| Nov 10, 2025 | $0.93 | $1.01 | Beat |
| Aug 5, 2025 | $0.94 | $1.00 | Beat |
| May 1, 2025 | $0.89 | $1.02 | Beat |